Theracryf (LON:TCF) Releases Earnings Results

Theracryf (LON:TCF) posted its earnings results on Tuesday. The company reported GBX (0.36) ($0.00) earnings per share (EPS) for the quarter, Digital Look Earnings reports. Theracryf had a negative net margin of 792.17% and a negative return on equity of 99.97%.

Theracryf Stock Performance

Shares of TCF opened at GBX 0.25 ($0.00) on Thursday. The firm has a market capitalization of £1.20 million, a price-to-earnings ratio of -0.24 and a beta of 1.42. The business’s fifty day moving average price is GBX 0.24 and its two-hundred day moving average price is GBX 0.47. Theracryf has a 52 week low of GBX 0.20 ($0.00) and a 52 week high of GBX 1.25 ($0.02).

About Theracryf

TheraCryf plc is a clinical stage therapeutics company developing a new generation of innovative therapeutics in oncology and behavioural brain disorders. TheraCryf’s strategy is to generate compelling data sets with a goal of partnering its programmes with mid-size to large pharma.

Formerly Evgen Pharma plc, the Company acquired Chronos Therapeutics in April 2024.